• Rayment, Jonathan


    Investigator, BC Children's Hospital
    Clinical Assistant Professor, Department of Pediatrics, University of British Columbia

    Degrees / Designations

    MD CM, MSc, FRCP(C)

    Primary Area of Research
    Childhood Diseases
    Secondary Area(s) of Research
    604-875-2345 ext. 4832
    Lab Phone
    Mailing Address

    BC Children's Hospital
    Room 1C19
    4480 Oak St
    Vancouver, BC V6H 3N1

    Affiliate Websites
    Research Areas
    • Paediatric lung disease
    • Cystic fibrosis
    • Biomarkers
    • Multiple breath washout
    • Pulmonary function testing
    • Magnetic resonance imaging

    I am interested in the development of new tools that will help us detect lung disease in children. Specifically, this includes new, more sensitive breathing tests that will help us measure lung function in children. As well, I am interested in developing new imaging tests (such as MRI) that will help us see the structure of the lung. 

    My research focuses primarily, but not exclusively, on patients with cystic fibrosis.

    Current Projects

    Due to the remarkable advances in the care of children with cystic fibrosis (CF) over the past 3 decades, the traditional pulmonary function tests in most paediatric CF patients are normal. Despite this, we know that there is structural damage, inflammation and infection in the lungs of these children from an early age. In addition, new medical therapies for CF are leading to a monumental shift in how this disease is treated -- but again, if traditional pulmonary function testing is "normal" at the onset of therapy, it will not be sufficient to monitor response to treatment. For these reasons, new markers of lung health and disease are needed in this population. My research interests focus on the development of two types or pulmonary biomarkers: pulmonary function and imaging.

    Multiple breath washout (MBW) testing is an old technique that has re-emerged in the literature over the past decade because it is extremely sensitive to the small airways disease that we see in early CF lung disease. There is, however, much that we don't know about this testing modality: how can/should it be used in a clinical setting? What constitutes a significant change between visits? Should a significant change in MBW outcomes prompt a change in clinical management? Through industry-initiated clinical trials and investigator-initiated studies, we hope to address these questions about this exciting new test.

    Magnetic responance imaging is traditionally ineffective for imaging lung tissues, to its low proton density and high number of air/tissue interfaces. Novel techniques such as ultrashort echo time (UTE) MRI are improving the spatial resolution of pulmonary MRI, and are now being tested in children with CF. In addition, gas contrast imaging of the lungs using inhaled hyperpolarized noble gases (helium or xenon) allows for functional imaging. In collaboration with partners at UBC and St Paul's Hospital, I hope to develop a pediatric lung imaging research group at BCCH to use these emerging technologies in the investigation and care of children with lung disease. 

    Selected Publications

    CF Canada Clinical Fellowship 2016-17

    Honours & Awards

    2017 North American Cystic Fibrosis Conference Junior Clinical Investigator of the Year

    Research Group Members